AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference
March 29, 2019 02:00 ET
|
AC Immune SA
Demonstrated high-affinity binding to human Parkinson's disease-brain derived alpha-synuclein Potentially first diagnostic for detecting and monitoring Parkinson's disease Further reinforces...
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
March 29, 2019 02:00 ET
|
AC Immune SA
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther reinforces...
New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference
March 27, 2019 07:01 ET
|
AC Immune SA
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSPNew data further support 18F-PI-2620's potential as a new PET Tracer for...
New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
March 27, 2019 07:00 ET
|
AC Immune SA
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as a new PET Tracer for...
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
March 21, 2019 07:00 ET
|
AC Immune SA
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023Eli Lilly deal validates MorphomerTM platformInitiation of second Phase 2 trial of Tau antibody by partner...
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
March 21, 2019 07:00 ET
|
AC Immune SA
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody by partner Genentech ...
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress
March 04, 2019 10:28 ET
|
AC Immune SA
Lausanne, Switzerland, March 4, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
March 04, 2019 09:59 ET
|
AC Immune SA
LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
February 20, 2019 07:00 ET
|
AC Immune SA
Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage...
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
February 07, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...